ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,749.00
0.35%
S&P ASX All Technology
3,067.50
0.14%
Brent Oil
82.585
0.00%
US Dollar vs AUD
1.50761
0.00%
Bitcoin
61,036.49
0.39%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lantern Pharma Inc (LTRN)

  7. Lantern Pharma Inc (LTRN) News

LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LTRN
DateTimeSourceHeadlineSymbolCompany
10/05/202406:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
10/05/202406:02Business WireLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
06/05/202417:00Business WireOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismNASDAQ:LTRNLantern Pharma Inc
02/05/202421:30Business WireLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
24/04/202422:00Business WireLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentNASDAQ:LTRNLantern Pharma Inc
22/04/202422:12Business WireLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanNASDAQ:LTRNLantern Pharma Inc
19/03/202407:02Business WireLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
18/03/202422:12IH Market NewsAnticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See UpticksNASDAQ:LTRNLantern Pharma Inc
15/03/202423:00Business WireLantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284NASDAQ:LTRNLantern Pharma Inc
11/03/202422:30Business WireLantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
06/03/202400:01Business WireLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceNASDAQ:LTRNLantern Pharma Inc
05/03/202400:01Business WireLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development TimelinesNASDAQ:LTRNLantern Pharma Inc
01/03/202413:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
16/02/202400:01Business WireLantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor CancersNASDAQ:LTRNLantern Pharma Inc
20/01/202408:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
17/01/202423:30Business WireStarlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical OfficerNASDAQ:LTRNLantern Pharma Inc
30/12/202308:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
01/12/202322:02Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LTRNLantern Pharma Inc
01/12/202322:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
01/12/202300:00Business WireFDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)NASDAQ:LTRNLantern Pharma Inc
25/11/202308:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
09/11/202308:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
09/11/202308:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
09/11/202308:01Business WireLantern Pharma Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:LTRNLantern Pharma Inc
01/11/202323:00Business WireLantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
21/10/202308:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
10/10/202323:00Business WireLantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
03/10/202323:00Business WireLantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in GlioblastomaNASDAQ:LTRNLantern Pharma Inc
25/09/202322:30Business WireLantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid TumorsNASDAQ:LTRNLantern Pharma Inc
18/09/202323:00Business WireLantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s LymphomasNASDAQ:LTRNLantern Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LTRN

Your Recent History

COIN
TRFBTC
LSE
QK98
Morg.st.b.v 26
COIN
TMCUSD
TMC
LSE
0NQY
Titan Cement
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved